IP Library Granted Patent US 10,548,868
Granted Patent B2
US 10,548,868 · App. 15/113,654 · Granted Feb 4, 2020

Metabolism-improving agent comprising rare fatty acid

Inventors: Jun Ogawa (Kyoto, JP); Shigenobu Kishino (Kyoto, JP); Teruo Kawada (Kyoto, JP); Nobuyuki Takahashi (Kyoto, JP); Tsuyoshi Goto (Kyoto, JP); Yasunori Yonejima (Muko, JP)
Assignees: KYOTO UNIVERSITY; NITTO PHARMACEUTICAL INDUSTRIES, LTD.
A61K31/202A61K31/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,548,868
App. No.
15/113,654
Granted
Feb 4, 2020
Kind
B2
Abstract

The present invention provides a metabolism improving agent containing a rare fatty acid such as hydroxylated fatty acid, oxo fatty acid and the like, and further, food, pharmaceutical product and the like containing the metabolism improving agent.

Claims (14)

1. A method for the treatment of hyperlipidemia, comprising administering to a patient having hyperlipidemia an effective amount of a fatty acid selected from the group consisting of

13-hydroxy-cis-9,cis-15-octadecadienoic acid, 10-oxo-13-hydroxy-cis-15-octadecenoic acid, 13-oxo-cis-6,cis-9-octadecadienoic acid, 13-oxo-cis-9,cis-15-octadecadienoic acid, and 10,13-dioxo-cis-15-octadecenoic acid.

2. The method according to claim 1 , wherein an effective amount of 13-hydroxy-cis-9,cis-15-octadecadienoic acid is administered to the patient.

3. A method for promoting a PPAR activity, wherein the PPAR is PPARα or PPARγ, comprising administering to a patient having hyperlipidemia an effective amount of a fatty acid selected from the group consisting of

13-hydroxy-cis-9,cis-15-octadecadienoic acid, 10-oxo-13-hydroxy-cis-15-octadecenoic acid, 13-oxo-cis-6,cis-9-octadecadienoic acid, 13-oxo-cis-9,cis-15-octadecadienoic acid, and 10,13-dioxo-cis-15-octadecenoic acid.

4. The method according to claim 3 , wherein an effective amount of 13-hydroxy-cis-9,cis-15-octadecadienoic acid, is administered to the patient.

5. The method according to claim 3 , wherein an effective amount of 10-oxo-13-hydroxy-cis-15-octadecenoic acid is administered to the patient.

6. The method according to claim 3 , wherein an effective amount of 13-oxo-cis-6,cis-9-octadecadienoic acid is administered to the patient.

7. The method according to claim 3 , wherein an effective amount of 13-oxo-cis-9,cis-15-octadecadienoic acid is administered to the patient.

8. The method according to claim 3 , wherein an effective amount of 10,13-dioxo-cis-15-octadecenoic acid is administered to the patient.

9. The method according to claim 1 , wherein an effective amount of 10-oxo-13-hydroxy-cis-15-octadecenoic acid is administered to the patient.

10. The method according to claim 1 , wherein an effective amount of 13-oxo-cis-6,cis-9-octadecadienoic acid is administered to the patient.

11. The method according to claim 1 , wherein an effective amount of 13-oxo-cis-9,cis-15-octadecadienoic acid is administered to the patient.

12. The method according to claim 1 , wherein an effective amount of 10,13-dioxo-cis-15-octadecenoic acid is administered to the patient.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE PROPERTY TYPE FROM APPLICATION NUMBER TO PATENT NUMBER FOR 10952983 AND 10975397 PREVIOUSLY RECORDED AT REEL: 68851 FRAME: 663. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 18, 2024
From: KYOTO UNIVERSITY
To: NOSTER INC.
Reel/Frame 069207/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2024
From: KYOTO UNIVERSITY
To: NOSTER INC.
Reel/Frame 068851/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2021
From: NITTO PHARMACEUTICAL INDUSTRIES, LTD.
To: NOSTER INC.
Reel/Frame 055920/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2016
From: OGAWA, JUN; KISHINO, SHIGENOBU; KAWADA, TERUO; TAKAHASHI, NOBUYUKI; GOTO, TSUYOSHI; YONEJIMA, YASUNORI
To: KYOTO UNIVERSITY; NITTO PHARMACEUTICAL INDUSTRIES, LTD.
Reel/Frame 039235/0668 →
Priority Claims (1)
JP 2014-011871 · Jan 24, 2014 · national
Continuity (1)
Related Publication 20170007564A1 · Jan 12, 2017